Noel Doheny - Epigenomics CEO of Epigenomics Inc.
| EPGNF Stock | USD 0.79 0.00 0.00% |
CEO
Mr. Noel Doheny was Chief Executive Officer of Epigenomics Inc. of Epigenomics AG since May 2011. He has 30 years of experience in the field of diagnostics, with over 20 years in senior management. Prior to joining Epigenomics, he held positions as CEO of OpGen, Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of PreAnalytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. He has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, Biostar, and OpGen. Noel obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for postgraduate studies in Biochemistry prior to moving into industry. since 2011.
| Tenure | 14 years |
| Phone | 49 30 243 450 |
| Web | https://www.epigenomics.com |
Epigenomics Management Efficiency
The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CEO Age | ||
| John Adent | Neogen | 57 | |
| Helmy Eltoukhy | Guardant Health | 46 | |
| Jacob Thaysen | Illumina | 50 | |
| Steven Chapman | Natera Inc | 46 | |
| Thierry Bernard | Qiagen NV | 61 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 |
Epigenomics AG Leadership Team
Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Hamilton, CEO Board | ||
| Frederic Hilke, Investor Officer | ||
| Jens Ravens, CFO Board | ||
| Noel Doheny, CEO of Epigenomics Inc. | ||
| Andrew Lukowiak, Pres Officer |
Epigenomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Epigenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 4.86 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Epigenomics Pink Sheet
Epigenomics financial ratios help investors to determine whether Epigenomics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Epigenomics with respect to the benefits of owning Epigenomics security.